A pharmaceutical composition, containing as active principle cyclobenzaprine hydrochloride, 3-(5H-dibenzo[a,d]cyclo-epten-5-yliden)-N,N-dimethyl-1-propanamine hydrochloride, in form suitable to be administered by itranasal route, is described. Said pharmaceutical composition allows a remarkable absorption rapidity of the active principle, does not undergo the first hepatic passage, has an excellent tolerability with low tonicity formulations and does not show any contraindication in the short period administrations.
